Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
BF Haynes, K Wiehe, P Borrow, KO Saunders… - Nature Reviews …, 2023 - nature.com
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
Major scientific hurdles in HIV vaccine development: historical perspective and future directions
T Ng'uni, C Chasara, ZM Ndhlovu - Frontiers in immunology, 2020 - frontiersin.org
Following the discovery of HIV as a causative agent of AIDS, the expectation was to rapidly
develop a vaccine; but thirty years later, we still do not have a licensed vaccine. Progress …
develop a vaccine; but thirty years later, we still do not have a licensed vaccine. Progress …
Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology
While antibody titers and neutralization are considered the gold standard for the selection of
successful vaccines, these parameters are often inadequate predictors of protective …
successful vaccines, these parameters are often inadequate predictors of protective …
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination
HIV-1–specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc
receptors. Antibodies of the same epitope specificity but of a different subclass therefore can …
receptors. Antibodies of the same epitope specificity but of a different subclass therefore can …
Immune correlates of vaccine protection against HIV-1 acquisition
L Corey, PB Gilbert, GD Tomaras, BF Haynes… - Science translational …, 2015 - science.org
The partial efficacy reported in the RV144 HIV vaccine trial in 2009 has driven the HIV
vaccine field to define correlates of risk associated with HIV-1 acquisition and connect these …
vaccine field to define correlates of risk associated with HIV-1 acquisition and connect these …
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk
HVTN 505 is a preventative vaccine efficacy trial testing DNA followed by recombinant
adenovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered …
adenovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered …
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial
Neutralizing and non-neutralizing antibodies to linear epitopes on HIV-1 envelope
glycoproteins have potential to mediate antiviral effector functions that could be beneficial to …
glycoproteins have potential to mediate antiviral effector functions that could be beneficial to …
Infectious RNA: human immunodeficiency virus (HIV) biology, therapeutic intervention, and the quest for a vaccine
Y van Heuvel, S Schatz, JF Rosengarten, J Stitz - Toxins, 2022 - mdpi.com
Different mechanisms mediate the toxicity of RNA. Genomic retroviral mRNA hijacks infected
host cell factors to enable virus replication. The viral genomic RNA of the human …
host cell factors to enable virus replication. The viral genomic RNA of the human …
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
The development of an effective AIDS vaccine remains a challenge. Nucleoside-modified
mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of …
mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of …
[HTML][HTML] Non-neutralizing antibodies alter the course of HIV-1 infection in vivo
Non-neutralizing antibodies (nnAbs) to HIV-1 show little measurable activity in prevention or
therapy in animal models yet were the only correlate of protection in the RV144 vaccine trial …
therapy in animal models yet were the only correlate of protection in the RV144 vaccine trial …